Table 1.

Demographics and baseline characteristics of the study patients

Characteristic	No Strontium-89 (n=40)		Strontium-89 (n=39)		Total (n=79)*
	n	%	n	%	n	%
Extent of Disease (Stratification)
1: ≤ 6 Bone Mets	18	45.0%	19	48.7%	37	47%
2: > 6 Bone Mets	22	55.0%	20	51.3%	42	53%
Unknown	0	0.0%
Demographics
Age (years):
Range	40	46–82	39	46–77	79	46–82
Median		63		62		63
Race and Ethnicity:
White	34	85.00%	37	94.87%	71	90%
Black	3	7.50%	2	5.13%	5	6.25%
Not Reported	3	7.50%	0	0.00%	3	3.75%
PSA (ng/mL):	40		39		79
Range		0.1–124.6		0.1–995.6		0.1–995.6
Median		2.5		5.4		3.7
LDH (IU/L):	40		39		79
Range		152–1021		124–886		124–1021
Median		470		431		459
Alkaline Phosphatase (IU/L):	40		39		79
Range		31–2679		48–1212		31–2679
Median		127		99		127
ECOG:
0	22	55%	29	74%	51	65%
1	16	40%	9	23%	25	31%
2	0	0%	0	0%	0	0%
3	2	5%	1	3%	3	4%
Gleason Score:
10, 9, 8	24	60%	26	67%	50	63.3%
7	11	27.5%	9	23%	20	25.3%
<7	0	0%	1	2.3%	1	1.3%
Not reported	5	12.5%	3	7.7%	8	10.1%
Previous treatments:
Surgery only	27	68%	23	59%	50	63%
Chemotherapy only			1	3%	1	1%
Combination therapy including surgery, chemotherapy and/or XRT	7	17%	7	18%	14	18%
No prior therapy	6	15%	8	20%	14	18%
Other features:
Lymph Node involvement	6	15%	8	20%	14	18%
Visceral Metastasis	0	0%	0	0%	0	0%

^*One patient withdrew consent after the screening procedures. (Mets: Metastasis, PSA: Prostate specific antigen, LDH: Lactate dehydrogenase, XRT: Radiation theraphy)